Skip to main content

Peer Review reports

From: A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

Original Submission
26 Oct 2019 Submitted Original manuscript
30 Dec 2019 Reviewed Reviewer Report - Kirsty Loudon
14 Jan 2020 Author responded Author comments - Joseph Chen
Resubmission - Version 2
14 Jan 2020 Submitted Manuscript version 2
Publishing
18 Jan 2020 Editorially accepted
10 Feb 2020 Article published 10.1186/s13063-020-4089-6

You can find further information about peer review here.

Back to article page

Trials

ISSN: 1745-6215